Yale University
The purpose of this study is to design and Beta test the Life at 100.4, an immersive social virtual reality education tool, with an anticipated 5 patient-caregiver-provider triads.Patients at Yale Pediatric Hematology and Oncology with a new oncologic diagnosis and their caregivers will be eligible for enrollment. Investigators will determine the feasibility and acceptability of implementing Life at 100.4 using validated measures.
Febrile neutropenia, a condition marked by fever and low numbers of neutrophils, is the most commonly encountered complication of childhood cancer treatment. The mortality of untreated febrile neutropenia is as high as 30%. Delay of appropriate care and increased time to antibiotics are associated with increased mortality. Reasons for delay to care include a lack of understanding about the seriousness of febrile neutropenia or difficulty navigating the healthcare system. Effective, and evidence-based educational experiences can reduce morbidity and mortality rates related to febrile neutropeni…
Inclusion Criteria: * Newly diagnosed with a malignancy or bone marrow failure condition * Planned to receive chemotherapy and receive a central line Exclusion Criteria: * Medical contraindication to virtual reality including head wounds and history of seizure with flashing lights * No plan to receive chemotherapy
An Immersive Social Virtual Reality Education Tool, participation up to 2 hours
Arctuva estimate
Verify or correct the compensation shown for this listing.